Download full-text PDF |
Source |
---|
Am J Clin Dermatol
January 2025
Department of Dermatology, University of Michigan, Ann Arbor, MI, USA.
Background: Cutaneous lupus erythematosus (CLE) is an autoimmune condition characterized by a wide range of clinical manifestations and limited treatment options. There is little research on the impact of commonly used diagnostic tests including antinuclear antibodies (ANA) and extractable nuclear antigens (ENA) on disease course or responsiveness to treatment.
Objective: This single-center retrospective cohort study aims to address this gap by characterizing clinicopathological characteristics, patient demographics, and treatment response among patients with CLE.
Ann Biol Clin (Paris)
November 2024
Laboratoire d'Immunologie, Centre de Recherche Clinique, CHU Mohammed VI, Marrakech, Maroc, Laboratoire de Recherche en Biosciences, Faculté de Médecine et de Pharmacie, Université Cadi Ayyad, Marrakech, Maroc.
Anti-Jo1 antibodies are usually known markers of myositis. However, they can be associated with different pathologies. We aimed to determine the immuno-clinical characteristics of patients with positive anti-Jo1.
View Article and Find Full Text PDFAnn Med Surg (Lond)
November 2024
Palestine Medical Complex, Internal Medicine, Ramallah, State of Palestine.
Lupus
December 2024
Division of Rheumatology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Objective: to investigate the trend of autoantibody titers during a 2-year follow-up in pediatric systemic lupus erythematosus (pSLE) and pediatric Sjögren's syndrome (pSS).
Methods: Autoantibodies testing was performed every 3-4 months during 2 years from disease onset in a cohort of children with pSLE and pSS.
Results: We enrolled 21 children with pSLE and 22 children with pSS.
Rheumatology (Oxford)
October 2024
University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, Turin, Italy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!